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ABSTRACT
Background Community-acquired pneumonia (CAP)
causes considerable morbidity and mortality in adults,
particularly in the elderly.
Methods Structured searches of PubMed were
conducted to identify up-to-date information on the
incidence of CAP in adults in Europe, as well as data on
lifestyle and medical risk factors for CAP.
Results The overall annual incidence of CAP in adults
ranged between 1.07 to 1.2 per 1000 person-years and
1.54 to 1.7 per 1000 population and increased with age
(14 per 1000 person-years in adults aged ≥65 years).
Incidence was also higher in men than in women and in
patients with chronic respiratory disease or HIV infection.
Lifestyle factors associated with an increased risk of CAP
included smoking, alcohol abuse, being underweight,
having regular contact with children and poor dental
hygiene. The presence of comorbid conditions, including
chronic respiratory and cardiovascular diseases,
cerebrovascular disease, Parkinson’s disease, epilepsy,
dementia, dysphagia, HIV or chronic renal or liver disease
all increased the risk of CAP by twofold to fourfold.
Conclusion A range of lifestyle factors and underlying
medical conditions are associated with an increased risk
of CAP in European adults. Understanding of the types of
individual at greatest risk of CAP can help to ensure that
interventions to reduce the risk of infection and burden of
disease are targeted appropriately.
INTRODUCTION
Community-acquired pneumonia (CAP) is a cause
of considerable morbidity and mortality in adults in
developed countries, leading to high rates of hospi-
talisations, especially in the elderly.1 2 The 2010
Global Burden of Disease Study reported that lower
respiratory tract infections, including pneumonia,
are the fourth most common cause of death globally,
exceeded only by ischaemic heart disease, strokes
and chronic obstructive pulmonary disease (COPD),
and they are the second most frequent reason for
years of life lost.3 Within Europe, CAP is the leading
cause of death due to infection,2 with approximately
90% of deaths due to pneumonia occurring in
people aged >65 years.4 Pneumonia places a consid-
erable burden on healthcare resources and society,
with associated annual costs in Europe estimated at
approximately €10 billion, mainly due to hospital-
isation and lost working days.5
Several risk factors for CAP are recognised, includ-
ing age >65 years,1 6 7 smoking,6 alcoholism,7
immunosuppressive conditions,7 and conditions such
as COPD,8 cardiovascular disease, cerebrovascular
disease, chronic liver or renal disease, diabetes melli-
tus and dementia.9 Although many European studies
have reported on the incidence of CAP and associated
risk factors, no comprehensive overviews of these
data are currently available. This literature review
was conducted to generate up-to-date information on
the incidence of CAP in adults in Europe, and of the
risk factors for contracting CAP. A secondary object-
ive was to collect data on the rates of comorbidities
in patients with CAP.
METHODS
The PubMed database was searched using the fol-
lowing search string: pneumonia AND English
AND 2005/01/01–2012/07/31 AND risk NOT clin-
ical trial, phase i OR clinical trial, phase ii OR clin-
ical trial, phase iii OR controlled clinical trial OR
randomised controlled trial OR case reports OR
practice guideline OR editorial OR review OR cost
OR cost effectiveness OR efficacy OR immunogen-
icity OR economic OR nosocomial. Additional
searches used the same search string, but replaced
‘risk’ with either ‘comorbidity’ or ‘co-morbidity’.
Papers were included if they reported observa-
tional studies performed in Western European
countries (Austria, Belgium, Denmark, Finland,
France, Germany, Greece, Ireland, Italy, The
Netherlands, Norway, Portugal, Spain, Sweden,
Switzerland, UK) and presented data from indivi-
duals aged >15 years on any of the following: inci-
dence of CAP in at-risk individuals, defined as
those with underlying risk factors for contracting
CAP (table 1); risk factors for CAP; comorbidities
in patients with CAP; pharmacotherapeutic agents
associated with an increase or decrease in the risk
of CAP; pathogens identified in patients with CAP.
Studies that focused on nosocomial or healthcare
acquired pneumonia were excluded.
Included papers were reviewed in full and data
on the study setting and methodology, characteris-
tics of the study population, incidence of CAP, risk
factors for CAP (ORs or relative risks (RRs), and
95% CIs) reported in case-control studies, and
observational data on rates of comorbidities, asso-
ciated pharmacotherapies and pathogens were col-
lected. If more than one paper reported different
aspects of the same study, all relevant papers were
included. Where the same data were reported in
more than one paper, the earliest published paper
was selected.
Analysis of the included papers was descriptive
and no meta-analyses of data were performed.
Unless otherwise stated, all data are reported as OR
(95% CI) or RR (95% CI).
RESULTS
Included studies
Of the 3330 references identified, 3240 were
excluded on the basis of the title or abstract. The
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authors identified one additional reference10 that did not
include the terms ‘risk’ or ‘co-morbidity’/’comorbidity’ in the
title or abstract and was therefore not identified in the PubMed
searches. However, it satisfied the other inclusion criteria. Final
screening of the full papers identified 61 references meeting the
inclusion and exclusion criteria, of which one paper11 was later
excluded due to data discrepancies that we were unable to
resolve by correspondence with the author (figure 1).
Of the 60 publications, a majority (34) focused on hospitalised
patients. Included studies were from Denmark (n=7), France
(n=5), Germany (n=5), Greece (n=1), Italy (n=4),
The Netherlands (n=3), Spain (n=23) and the UK (n=12).
Study designs and populations are summarised in online supple-
mentary table S1. Most studies included adults of all ages.
However, five studies considered only patients aged
≥65 years,12–16 two included patients aged 50–65 years,17 18 two
included patients aged ≥45 years19 20 and single studies included
patients aged ≥30 years,21 ≥40 years22 or 16–40 years.23 Six
studies included only patients infected with HIV.24–29
Most studies included patients with pneumonia of any aeti-
ology, but six were performed in patients with pneumonia due
to a specified bacterial agent: four studies in patients with
Legionella pneumophila infection,30–33 and one each in patients
with Haemophilus influenzae34 or Gram-negative bacteria35
infections.
Incidence of CAP
The incidence of CAP was reported in 16 studies, from Denmark
(n=2),17 18 France (n=3),24 26 29 Germany (n=1),36 Italy
(n=2),27 37 Spain (n=5)16 25 38–40 and the UK (n=3).19 41 42
Data are summarised in table 2, with more details available in
online supplementary table S2.
Differences in study populations and measures used for
incidence rates make it difficult to make direct comparisons
across studies. Nevertheless, several trends were apparent.
The overall annual incidence of CAP in adults ranged between
1.07 to 1.2 per 1000 person-years and 1.54 to 1.7 per 1000
population37 38 42 43 (table 2). Rates of hospitalisation for CAP
Figure 1 Summary of the study
selection procedure. CAP, community
acquired pneumonia. *One study did
not include the terms ‘risk’ or
‘co-morbidity’/’comorbidity’ in either
the title or abstract and so was not
identified in the PubMed searches;
however, ‘risk factors’ was included in
the list of MeSH terms for the article.
Table 1 Risk categories for community-acquired pneumonia included in the review
Immunocompetent at risk Immunocompromised at risk
▸ Age
▸ Lifestyle
– Alcoholism
– Smoking
▸ Underlying diseases
– Chronic heart disease
– Chronic renal disease
– Chronic liver disease
– Chronic respiratory disease
– Metabolic disease
– CNS disease
▸ Prior IPD
▸ Previous pneumonia
▸ Other
– Aspiration
– Concomitant treatment
▸ Immunosuppression
– Autoimmune diseases receiving steroid or immunosuppressive therapy or biological therapy
– Cancer with immunosuppressive treatment
– Waiting list for solid-organ transplantation (with or without immunosuppressive treatment)
– Other immunosuppression
▸ Immunocompromised
– Asplenia/splenic dysfunction
– Primary immunodeficiencies
▸ HIV
CNS, central nervous system; IPD invasive pneumococcal disease.
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Table 2 Incidence of community-acquired pneumonia (CAP) in adults in Europe
Study Country; region Study period CAP incidence (95% CI)
Overall population
Almirall et al38 Spain; east coast 1 November 1999–30 November 2000 Per 1000 population >14 years:
1.54
Gutierrez et al39 Spain; Alicante 15 October 1999–14 October 2001 Per 1000 person-years:
Overall, 1.230
Men, 1.556
Women, 0.911
Rodriguez et al42 UK; national 1 January 2000–31 December 2005 Primary care patients, per 1000 person-years:
Overall, 1.07 (1.04 to 1.09)
Women, 0.93 (0.89 to 0.96)
Men, 1.22 (1.18 to 1.26)
Viegi et al37* Italy; national 15 February 1999–14 February 2000 Annual incidence per 1000 population:
Overall, 1.703
Males, 1.692
Females, 1.713
Vila-Corcoles et al16 Spain; Tarragona 1 January 2002–30 April 2005 Age ≥65 years, per 1000 person-years:
Overall, 14.0 (12.7 to 15.3)
Men, 19.2 (17.1 to 21.6)
Women, 10.0 (8.6 to 11.5)
Hospitalisation for CAP
Bewick et al41 UK; Nottingham September 2008–September 2010 Per 1000 population ≥16 years: Overall, 1.097
Ewig et al36 Germany; national 2005 and 2006 Per 1000 population/year ≥18 years:
2005, 2.75
2006, 2.96
Mean incidence:
Men, 3.21
Women, 2.52
Kornum et al17 Denmark; Copenhagen and Aarhus December 1993–April 2008 Per 1000 person-years, >50 years:
Men, 4.2
Women, 3.4
Kornum et al18 Denmark; Copenhagen and Aarhus December 1993–April 2008 Per 1000 person-years, >50 years:
Men, 4.25
Women, 3.28
Patients with COPD
Müllerova et al19 UK; England and Wales 1 January 1996–31 December 2005 Per 1000 patient-years:
Overall, 22.4 (21.7 to 23.2)
Women, 21.4 (20.4 to 22.5)
Men, 23.1 (22.1 to 24.2)
Immunocompromised individuals
Perez-Sola et al40† Spain; national February 2000–January 2006 Patients with rheumatic diseases treated with TNF
antagonists, per 1000 patient-years:
5.97 (4.87 to 7.25)
HIV-infected individuals
Bénard et al24 France; Aquitaine 2000–2007 Per 1000 patient-years:
Overall: 12.0 (9.9 to 14.0)
Curran et al25 Spain; Barcelona January 2000–December 2005 Cases/1000 patients/year:
2000, 30.90
2001, 31.80
2002, 25.70
2003, 21.90
2004, 20.50
2005, 24.00
Le Moing et al26 France; national May 1997–December 2001 Hospitalisation for first episode of bacterial pneumonia in protease
inhibitor-treated patients:
8/1000 patient-years (3–13)
Madeddu et al27‡ Italy; northern Sardinia January 1999–December 2004 Per 1000 inpatients/year:
1999, 177
2004, 280
Saindou et al29 France; Lyon 1993–2004 Pneumococcal pneumonia, per 1000 patient-years:
Cohort followed 1993–1 July 1996 (pre-HAART), 10.6 (5.4 to 15.7)
Cohort followed before 1 July 1996–2004 (pre-HAART and
HAART era), 1.5 (0.9 to 2.1)
Cohort followed 1 July 1996–2004 (HAART era), 2.5 (1.4 to 3.6)
Incidence rates standardised per 1000 population or per 1000 person-years; original study data are available in online supplementary table S2.
*This study included data for 10 children aged <14 years.
†In this study, ‘pneumonia’ included fungal and viral aetiologies.
‡A majority of patients (84%) in this study were also intravenous drug users.
COPD, chronic obstructive pulmonary disease; HAART, highly active antiretroviral therapy; TNF, tumour necrosis factor.
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were typically higher than overall incidence rates; for example,
a German study36 reported rates of 2.75 and 2.96 per 1000
population/year aged ≥18 years in 2005 and 2006, respectively
(table 2). Overall CAP incidence and hospitalisation for CAP
were higher in men than in women. The overall incidence per
1000 person-years in a UK study was 1.22 (1.18 to 1.26) in
men compared with 0.93 (0.89 to 0.96) in women,42 whereas a
study in Denmark in men and women aged >50 years reported
rates of hospitalisation for pneumonia per 1000 person-years of
4.2 in men and 3.4 in women.17
The incidence of CAP increased with age and with the pres-
ence of comorbidities (see online supplementary table S2).
Among individuals aged ≥65 years in Spain, the incidence per
1000 person-years was 14.0 (12.7 to 15.3).16 A study of
patients with COPD reported the highest overall incidence of
22.4 (21.7 to 23.2) per 1000 person-years, with rates of 23.1
(22.1 to 24.2) and 21.4 (20.4 to 22.5) in men and women,
respectively.19
High incidence rates were also reported in immunocomprom-
ised patients (table 2). Among patients with rheumatic diseases
in Spain treated with tumour necrosis factor antagonists, the
incidence per 1000 patient-years was 5.97 (4.87 to 7.25).40 The
incidence in patients with HIV in France, was 12.0 (9.9 to 14.0)
per 1000 patient-years.24 However, highly active antiretroviral
therapy (HAART) appears to reduce the risk of CAP, with
another French study reporting a reduction from 10.6 (5.4 to
15.7) per 1000 patient-years in the pre-HAART era to 2.5 (1.4
to 3.6) in the post-HAARTera.29
Lifestyle factors and risk of CAP
The potential association between lifestyle factors and the risk of
CAP was investigated in 12 case-control studies, performed in
France (n=1),30 Germany (n=1),44 The Netherlands (n=1),23 45
Spain (n=2)12 38 and the UK (n=7).19–22 42 46 47 Study details
are summarised in online supplementary table S3.
There was consistent evidence that smoking was associated
with an increased risk of CAP.19–23 38 42 46 47 Compared with
non-smokers (OR 1.00), the risk of CAP was increased in
current smokers (crude ORs: 1.37 (1.14 to 1.64) to 1.81 (1.53
to 2.15); adjusted ORs: 0.99 (0.86 to 1.14) to 2.00 (1.20 to
3.36)) and former smokers (crude ORs: 1.34 (1.11 to 1.62) to
1.40 (1.17 to 1.68); adjusted OR: 1.04 (0.90 to 1.2)).
Compared with individuals who consumed no alcohol (OR
1.00), consumption of ≤40 g alcohol daily appeared to protect
against CAP (21–40 g/day, crude ORs: 0.53 (0.22 to 1.25) and
0.88 (0.63 to 1.22)).23 38 However, the risk increased in indivi-
duals with higher consumption (>41 g/day, crude OR: 1.59
(0.59 to 4.25)23; >80 g/day, crude OR: 2.34 (1.13 to 4.85)38)
or with a history of alcohol abuse/alcoholism (crude ORs: 1.85
(1.19 to 2.88)21 and 1.62 (0.91 to 2.91)47).
Being underweight was generally associated with an increased
risk of CAP (crude ORs: 1.04 (0.57 to 1.89) to 2.20 (1.57 to
3.09)23 38 44 47) compared with normal bodyweight (OR 1.00).
A reduced risk was seen in individuals classified as overweight
(crude ORs: 0.6 (0.5 to 0.7) to 0.89 (0.72 to 1.09)21 23 38 44 47;
adjusted ORs: 0.6 (0.5 to 0.7)44 and 0.78 (0.67 to 0.90)19),
whereas those classified as obese had either a lower risk (crude
ORs: 0.66 (0.58 to 0.75) to 0.81 (0.66 to 0.99)21 38 44 47;
adjusted ORs: 0.7 (0.5 to 0.9)44 and 0.71 (0.60 to 0.85)19) or
the same risk (crude OR 1.04 (0.57 to 1.89)23) as those of
normal weight.
Household arrangements were also associated with the risk of
CAP. Living in a household of over 10 people was associated
with a crude OR of 2.20 (1.21 to 4.00).38 Regular contacts with
children also increased the risk of CAP (crude OR: 1.48 (1.26
to 1.75)38). Two studies found that having children in the
household increased the adjusted OR from 1.00 for ‘no chil-
dren’ to 3.2 (1.5 to 7.0)44 or 3.41 (1.57 to 7.41)23 for three or
more children. There was no clear evidence regarding the influ-
ence of contact with pets; one study demonstrated an increased
risk of CAP (crude OR 1.37 (1.18 to 1.60)38), whereas a study
in young adults (aged 16–40 years) found a decreased risk
(crude OR 0.85 (0.58 to 1.24)23).
Higher levels of education were associated with a lower risk
of CAP.23 38 44 Compared with individuals with a low level of
education (OR 1.00), risk declined in those with an intermedi-
ate (secondary; crude ORs: 0.69 (0.41 to 1.19) to 0.86 (0.72 to
1.01)) or high level (university; crude ORs: 0.67 (0.41 to 1.10)
to 0.78 (0.64 to 0.96)).23 38 In another study, individuals with
≥12 years of education had a lower risk of CAP (adjusted OR
0.8 (0.6 to 1.1)) compared with those who had ≤9 years of edu-
cation (OR 1.00).44
Two studies found that visiting the dentist was associated with
a decreased risk of CAP (in the past month, crude OR 0.71
(0.55 to 0.92)38; in the past year, OR 0.59 (0.34 to 1.04)23). In
contrast, one study found that frequent visits to the general
practitioner in the previous year were associated with a substan-
tial increase in the risk of CAP (1–4 visits, OR 1.00; ≥30 visits,
crude OR 3.73 (3.14 to 4.42)).21
Comorbid conditions and risk of CAP
The association between comorbidities and the risk of CAP was
investigated in 14 case-control studies (Denmark (n=1),48
Germany (n=1),44 The Netherlands (n=1),23 Spain (n=2)12 38
and the UK (n=9)14 19–22 42 46 47 49 (see online supplementary
table S4).
A history of respiratory disease was associated with an
increased risk of CAP. A history of pneumonia increased the risk
of a subsequent episode (crude ORs: 2.39 to 6.25 (1.83 to
21.40)22 38 44). Patients with chronic respiratory diseases,
including COPD, bronchitis or asthma, had a twofold to four-
fold increase in the risk of CAP (crude ORs: 2.17 (1.99 to 2.37)
to 3.92 (3.67 to 4.18)12 14 21–23 38 44 46 47). Additional data
also support this association. One study reported an adjusted
OR of 2.47 (2.37 to 2.58) for chronic respiratory disease,20 and
another study reported adjusted RRs of 2.82 (2.45 to 3.24) for
COPD and 1.58 (1.44 to 1.74) for asthma.42 Patients with at
least one respiratory tract infection in the past year were also at
increased risk of CAP (crude ORs: 1.57 (1.35 to 1.84)38 to 4.5
(3.7 to 5.4)44). In young adults, the risk of CAP increased in
line with the number of infections over the previous 6 years (1–
2 infections, adjusted OR 1.49 (0.87 to 2.56); >3 infections,
adjusted OR 4.84 (1.24 to 18.9)).23
Chronic cardiovascular disease increased the risk of CAP up
to threefold (crude ORs from 1.4 (1.2 to 1.5) to 3.2 (2.6 to
4.1)12 21 22 38 44 46 47 49). Additional studies supported an asso-
ciation between chronic heart disease (adjusted ORs: 1.63 (1.54
to 1.72)46 and 1.66 (1.59 to 1.73)20) or heart failure (adjusted
ORs: 2.19 (0.69 to 6.95)12 and 1.37 (1.20 to 1.57)19; adjusted
RR: 2.63 (2.21 to 3.14)42) and the risk of CAP.
Cerebrovascular disease/stroke and dementia approximately
doubled the risk of CAP (for cerebrovascular disease/stroke,
crude ORs: 1.86 (1.74 to 1.99) to 2.37 (2.19 to 2.57),14 21 46 49
adjusted ORs: 1.08 (0.93 to 1.26)19 and 1.68 (1.58 to 1.77),20
adjusted RR: 1.42 (1.25 to 1.61)42 for dementia, crude ORs:
2.12 (0.91 to 4.94) to 2.41 (2.11 to 2.75),14 38 46 adjusted ORs:
2.64 (1.86 to 3.75)19 and 2.68 (2.42 to 2.97)20). Other neuro-
logical or psychiatric conditions were also associated with an
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increased risk of CAP in some studies (epilepsy, crude ORs: 2.81
(1.83 to 4.30) and 2.83 (1.11 to 7.21)21 38; Parkinson’s disease,
crude ORs: 1.82 (1.52 to 2.19) and 1.87 (1.60 to 2.19)14 46;
multiple sclerosis, crude OR 3.20 (2.40 to 4.26)46). Crude ORs
for CAP in patients with depression or bipolar disorder ranged
from 1.75 (1.65 to 1.86) to 2.54 (1.03 to 6.26).14 21 23 However,
the association with depression may have been confounded by
other factors, as other studies reported an adjusted OR of 1.13
(0.99 to 1.28)19 or an adjusted RR of 1.30 (1.19 to 1.40).42
Two studies in elderly patients found a strong association
between dysphagia and risk of CAP. A large database study in
patients aged ≥65 years reported a crude OR of 2.10 (1.85 to
2.38),14 whereas a small study in patients aged ≥70 years
reported a crude OR of 16.3 (4.57 to 58.2) and an adjusted OR
of 11.9 (3.03 to 46.9).12
Data from several studies suggested that diabetes mellitus was
associated with a moderate increase in the risk of CAP (crude
ORs: 1.43 (1.11 to 1.92) to 1.54 (1.44 to 1.65),21 38 46 adjusted
ORs: 1.07 (0.89 to 1.28)19 and 1.33 (1.26 to 1.41),20 adjusted
RRs: 1.26 (1.21 to 1.31)48 and 1.28 (1.13 to 1.44)42).
Cancer was also associated with a moderate increase in the
risk of CAP (crude ORs: 1.42 (1.04 to 1.92)38 and 1.70 (1.58
to 1.82),46 adjusted ORs: 1.42 (1.3 to 1.56)46 and 1.36 (1.24 to
1.49),20 adjusted RR: 1.37 (1.22 to 1.54)42). One study
reported a fivefold higher risk in patients with lung cancer
(crude OR: 4.73 (3.58 to 6.25)).46
Chronic liver or renal disease increased the risk of CAP
approximately twofold (chronic liver disease, crude ORs: 1.67
(0.99 to 2.82) to 2.24 (1.74 to 2.89),38 44 46 adjusted ORs: 1.87
(1.43 to 2.44)46 and 1.85 (1.48 to 2.31)20; chronic renal disease,
crude ORs: 1.7 (1.1 to 2.8)44 and 2.15 (1.81 to 2.56),46 adjusted
ORs: 1.72 (1.43 to 2.07)46 and 1.78 (1.53 to 2.07)20).
Associations between conditions affecting immune function
and the risk of CAP were reported. There was a moderate
increase in risk in patients with rheumatoid arthritis (crude
ORs: 1.46 (1.14 to 1.88)21 and 2.02 (1.79 to 2.29),46 adjusted
ORs: 1.84 (1.62 to 2.10)46 and 1.83 (1.64 to 2.03),20 adjusted
RR: 1.37 (1.12 to 1.69)42). Additionally, there was over a
twofold increase in risk in patients with asplenia (adjusted OR:
2.58 (1.80 to 3.71)46) or with HIV or AIDS (adjusted ORs:
2.48 (1.34 to 4.58)46 and 5.90 (2.55 to 13.64)20).
In addition to the above medical conditions, a moderate
increase in risk of CAP was reported in patients with anaemia
(adjusted RR: 1.43 (1.25 to 1.62)).42
Hospitalisation in the previous 5 years was associated with an
increased risk of CAP (crude ORs: 1.6 (1.4 to 1.9)44 and 1.68
(1.44 to 1.96)38). An adjusted RR of 1.77 (1.59 to 1.97) was
calculated in patients with more than one hospitalisation in the
previous year.42 The risk of CAP was increased in patients who
had undergone either bronchoscopy (crude OR: 2.09 (1.07 to
4.06)) or passage of a nasogastric tube (crude OR: 3.21 (1.17 to
8.77)) during the previous year.38
Comorbid conditions in patients with CAP
The frequency of comorbidities in patients diagnosed with CAP
was presented in 39 studies (7 case-control studies of observa-
tional data,15 19 45 50–53 and 31 observational, cohort studies10
13 16 27 28 31–37 41 43 54–70). Study details are summarised in
online supplementary table S5.
The most common comorbidities were chronic respiratory
diseases (up to 68% of patients), chronic heart disease (up to
47%) or heart failure (up to 46%), diabetes mellitus, cerebrovas-
cular diseases and dementia (all up to 33%; table 3). Chronic
liver and chronic renal diseases were observed in up to 20% and
27% of patients, respectively. The frequency of comorbidities
was generally higher in patients aged ≥65 years compared with
those aged <65 years, and in patients with COPD, chronic
renal failure or cirrhosis compared with those without such con-
ditions (see online supplementary table S5).
DISCUSSION
This review represents a comprehensive compilation of data
about the incidence of and risk factors for CAP in adults in
Western Europe.
Notwithstanding the heterogeneity of the populations studied
and measures of incidence rates used, overall the annual inci-
dence was 1.07–1.7 per 1000 population. Studies consistently
showed that the incidence was higher in men than in women,
and that it increased with age; in patients aged ≥65 years, an
incidence rate of 14 cases per 1000 person-years was
reported.16 These findings are consistent with those of a recent
review of European incidence rates published between 1990
and 2007.1 Also in line with previous studies of CAP epidemi-
ology, incidence rates were higher in patients with comorbidities
such as COPD,8 and in patients with HIV compared with those
without HIV.71 Possible explanations for the higher rates of hos-
pitalisation for CAP compared with overall incidence rates
include the inclusion of data from different countries (Italy,37
Spain38 43 and the UK42 for overall incidence rates; Denmark,17
18 Germany36 and the UK41 for hospitalisation) reflecting
national differences in medical practice, and that Danish studies
were performed in patients aged >50 years,17 18 and so repre-
sent a population at increased risk of CAP.1 2
Importantly, this review included data obtained from observa-
tional and case-control studies. While observational studies
provide valuable data on the rates of comorbidities observed in
patients with CAP, they do not permit their identification as risk
factors for infection. However, case-control studies of patients
allow us to establish which comorbidities are indeed risk factors
for CAP.
Pooled data from observational studies demonstrated the
overall burden of CAP in patients with other medical condi-
tions.10 13 16 27 28 31–37 41 43 54–70 Chronic respiratory diseases,
Table 3 Frequency of comorbid conditions in adults with
community-acquired pneumonia
Comorbid condition
Number of cohorts
with data*
Patients with
condition (%)
Previous pneumonia 10 3.2–33.8
Chronic respiratory
disease
25 9.7–68
COPD 21 9.4–62
Asthma 9 3–50.0
Chronic heart disease 23 10–47.2
Heart failure 27 1.0–46
Diabetes mellitus 48 4.9–33.0
Cerebrovascular disease/
stroke
26 3.2–33
Dementia 12 1.1–33.6
Cancer 33 4.3–18.0
Chronic liver disease 36 0.3–20
Chronic renal disease 39 0.5–26.7
*For studies that only reported data separately for each cohort, all cohorts were
included; for studies that reported data for the overall study population, the summary
data were used.
COPD, chronic obstructive pulmonary disease.
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cardiovascular diseases, cerebrovascular diseases, dementia and
diabetes mellitus were the most frequently observed comorbid-
ities. Up to two-thirds of patients had a chronic respiratory
disease and almost half had a chronic cardiovascular disease,
highlighting the need for appropriate management of these
patients to reduce their risk of CAP.
Lifestyle factors such as smoking, high alcohol intake, being
underweight, living in a large household or having regular
contact with children were associated with an increased risk of
CAP.12 19–23 30 38 42 44 46 47 Smoking is an established risk
factor for CAP,6 72 probably due to its adverse effects on the
respiratory epithelium and the clearance of bacteria from the
respiratory tract.73 Alcoholism has been associated with defects
in innate and adaptive immunity,74 and is a recognised CAP risk
factor.7 Smoking and excessive alcohol consumption are major
health risks globally and are targets for interventions to reduce
the global burden of disease.75 Ensuring that patients make
appropriate lifestyle changes would help to reduce the overall
burden of CAP. Being underweight may predispose patients to
CAP due to the consequences of undernutrition or underlying
conditions on immune function.6 44 72 76 Assessment of the
nutritional status of vulnerable patients might help to identify
those at increased risk of CAP. Regular contact with children has
also been identified previously as a risk factor for CAP, possibly
due to the high carriage of Streptococcus pneumoniae by chil-
dren.44 77 Appropriate measures for infection control may be
advisable in vulnerable patients who are in regular contact with
children.
Some lifestyle factors may provide protection against CAP.
Young adults who consumed <40 g of alcohol per day had a
lower risk of CAP than those who drank no alcohol,23 poten-
tially because individuals who consumed no alcohol had other
comorbidities that increased the risk of CAP. However,
light-to-moderate alcohol intake has been reported to reduce
the risk of atherosclerosis and cardiovascular disease,78 79 due
to the antioxidant activities of alcohol,78 and this may also
protect against CAP. Adherence to good dental hygiene was also
associated with a reduced risk of CAP. Poor oral care has previ-
ously been identified as a risk factor for nursing-home acquired
pneumonia, possibly due to the colonisation of the oral cavity
by respiratory pathogens,80 and this risk may also be relevant
for CAP. Finally, a higher level of education appeared to reduce
the risk of CAP compared with a low level of education, as
reported previously for invasive pneumococcal disease.81 A
similar protective association of higher educational levels has
also been described in relation to cardiovascular risk factors.82
Measures to reduce social and health inequalities could have the
benefit of reducing costs associated with diseases like CAP.
The review also provides robust evidence that several
comorbidities are associated with an increased risk of CAP,
including a history of respiratory disease (including pneumonia)
and cardiovascular disease. Patients with COPD are recognised
as having a high risk of CAP8 and are targets for vaccination
against influenza and pneumococcal disease,83 84 as are patients
with chronic cardiovascular diseases.84–86
Patients with cerebrovascular disease or stroke, and neuro-
logical disorders (dementia, epilepsy, Parkinson’s disease and
multiple sclerosis) had approximately twice the risk of CAP
compared with individuals without these conditions; dysphagia
was also associated with a substantial increase in risk. The use of
sedative medications and problems with swallowing might con-
tribute to the risk of CAP in patients with dementia,19 43 prob-
ably due to aspiration and its associated risk of pneumonia.87
This could apply to patients with other neurological disorders.
Other comorbid conditions associated with an increased risk
of CAP in the present study, including diabetes mellitus, cancer,
chronic liver or renal disease, and impaired immune function,
have previously been identified as risk factors for CAP.9
The main strength of this review is that many of the included
publications were of case-control studies performed in large
numbers of patients from registries or primary care databases,
rather than small, single-centre studies, providing reassurance
that the included studies provide a good representation of CAP
in European populations.
This review also has some limitations. Patient registries and
primary care databases are dependent on the quality of the
information included in the records, and rely on the accuracy of
the individuals responsible for entering diagnostic codes and
demographic data. However, the inclusion of several thousand
patients in such studies should help to minimise any potential
introduced bias. Most of the included studies were based on
patient populations in either Spain (23 studies10 12 13 16 25 32 33
35 38–40 43 50 54–59 63 65 68 69) or the UK (12 studies14 19–22 41
42 46 47 49 53 66), and this could limit the validity of the review
for extrapolating the data to other European populations. Only
those studies that were indexed in the PubMed database were
included, and data from, for example, national surveillance data-
bases were not included. Nevertheless, we believe it provides a
good representation of the incidence and risk factors for CAP in
European countries.
Lifestyle interventions, such as stopping smoking, reducing
alcohol consumption, having regular dental checks and
Table 4 Bundles for lifestyle interventions to reduce the risk of CAP in adults
Risk factor Evidence Recommendation
Smoking Risk of CAP increased in current and former
smokers (9 studies)19–23 38 42 46 47
Smoking cessation
Alcohol consumption Risk of CAP increased with high consumption or history of alcohol
abuse (4 studies)21 23 38 47
Reduce alcohol consumption
Nutritional status Being underweight was generally associated with an increased risk of
CAP (4 studies)23 38 44 47
Dietary advice to ensure good nutritional status
Contact with children Regular contact with children increased the risk of CAP (3
studies)23 38 44
Avoid contacts with children with lower respiratory
tract infections
Dental hygiene Risk of CAP decreased in individuals with a recent (within past year)
dental visit (2 studies)23 38
Ensure regular dental visits
Vaccination against influenza and
Streptococcus pneumoniae
Current guidelines88 89 Ensure compliance with guidelines
CAP, community-acquired pneumonia.
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maintaining good nutritional status could help to reduce the
burden of CAP. Patients with conditions such as chronic respira-
tory, cardiovascular and neurological diseases should be
managed in accordance with current clinical guidelines to opti-
mise their overall health status, and elderly patients should try
to minimise contact with children who have acute viral respira-
tory infections. Finally, adults at risk of CAP should be vacci-
nated against influenza and pneumococcal pneumonia to reduce
the risk of lower respiratory tract infections, in accordance with
current guidelines (table 4).88 89
All but six of the studies included patients with pneumonia of
any aetiology. S pneumoniae is the most frequently isolated
pathogen from patients with CAP in Europe,1 and has been esti-
mated to be the cause of 30–50% cases of CAP requiring hospi-
talisation in adults in developed countries.90 A 23-valent
pneumococcal polysaccharide vaccine is recommended in some
countries for the routine vaccination of adults aged ≥65 years,
and for patients at increased risk of CAP.85 86 However, there is
little evidence that it is effective in elderly people or adults with
chronic diseases.91 92 A 13-valent pneumococcal conjugate
vaccine (PCV-13) is available for the prevention of pneumonia
and invasive pneumococcal disease caused by PCV-13 serotypes
in adults aged ≥18 years.93 Efficacy of PCV-13 for the preven-
tion of a first episode of vaccine serotype-specific pneumococcal
CAP in community-dwelling adults aged ≥65 years is being
investigated in the ongoing Community Acquired Pneumonia
Immunisation Trial in Adults.94
In conclusion, this review of risk factors for CAP in European
adults has highlighted the range of lifestyle factors and under-
lying medical conditions that are associated with an increased
risk of infection. Lifestyle factors included smoking, alcohol
abuse, being underweight and regular contact with children,
whereas patients with chronic respiratory or cardiovascular dis-
eases, cerebrovascular disease, epilepsy, dementia, dysphagia,
HIV, or chronic renal or liver disease were all at increased risk
of CAP. Greater understanding of the types of individuals at risk
of CAP can help to ensure that interventions to reduce the risk
of infection and burden of disease are targeted appropriately.
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